Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

While Novo Nordisk is mostly focused on diabetes and obesity (however, Novo Nordisk also tried to diversify in the last few years – also by some acquisitions), Eli Lilly is not only focused on ...

Lilly shares were off 8%, wiping out nearly $70 billion from the Indianapolis-based drugmaker's market value. Both its weight-loss drug Zepbound and diabetes treatment Mounjaro have been ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Company shares slipped in trading after the announcement. Sales of Lilly’s diabetes treatment Mounjaro and weight loss counterpart Zepbound were hurt in the quarter as U.S. pharmaceutical wholesalers ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

At the core of the disappointing results were weaker-than-expected revenue from Eli Lilly’s GLP-1 drug tirzepatide sold under the brand names Mounjaro for type 2 diabetes and Zepbound for weight ...

What's behind Lilly's disappointing Q3 update? Type 2 diabetes drug Mounjaro and weight-loss drug Zepbound remained the brightest stars in Lilly's lineup. Mounjaro's sales more than doubled year ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Lilly's blockbuster weight-loss drug Zepbound and diabetes drug Mounjaro remain bright spots, as the GLP-1 drug portfolio remains a focal point of the company's earnings story. But revenue from ...